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Abstract
Introduction: The Vaccine Adverse Event Reporting System (VAERS) is the spontaneous 
(passive) reporting system CDC and FDA use to monitor vaccine safety. We used cognitive testing 
to evaluate proposed revisions to the current VAERS form.
Methods: We conducted in-person cognitive interviews with 22 volunteers to evaluate proposed 
revisions in a prototype VAERS 2.0 form (new VAERS form). We analyzed data using thematic 
analysis.
Results: Repeating themes included preferences for: brevity, simplicity and clarity; features to 
minimize time requirements and facilitate ease of completion; logical ordering of questions by 
topic and importance; and visual cues like color-coded highlighting. Interviews identified 
instances of discordance between the intended meaning questions (from the perspective of CDC 
and FDA) and interpretation by volunteers.
Conclusions: Cognitive testing yielded useful information to guide further revisions of the 
VAERS form. Cognitive testing can be an effective tool for public health programs interested in 
developing surveys and reporting forms.
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1. Introduction
Vaccines undergo rigorous testing for safety and effectiveness prior to licensure [1]. After 
licensure, the Centers for Disease Control and Prevention (CDC) and US Food and Drug 
Administration (FDA) jointly monitor safety using the Vaccine Adverse Event Reporting 
System (VAERS) [2]. VAERS is a national spontaneous (passive) monitoring system for 
detecting possible safety signals. It relies on individuals to voluntarily report experiences of 
adverse events (AE) following vaccination. In recent years, 26% of reports have come from 
healthcare professionals, 11% from patients and parents, 12% from “others” and 51% from 
vaccine manufacturers (CDC unpublished data). As such, the VAERS reporting form and 
reporting process must accommodate individual reporters with varying backgrounds and 
education levels.
The VAERS-1 paper reporting form [3] has been in use since 1990, but little qualitative 
research has been done to evaluate public perception and understanding of its questions. 
CDC and FDA have identified data elements on the VAERS-1 form that have limited value 
for safety monitoring. Furthermore, important data elements are absent (e.g., information on 
pregnancy), and other existing data elements required language clarification. CDC and FDA 
are presently updating the VAERS-1 form to revise questions, improve ease of completion, 
and transition to a computer-based form that can be submitted electronically using the 
Internet (the new VAERS 2.0 form) [4]. To evaluate proposed revisions, CDC conducted 
cognitive testing of a prototype VAERS 2.0 form.
2. Methods
Cognitive testing is used to evaluate how people interpret survey questions and to gain 
insight into cognitive processes used when completing surveys, with the goal of improving 
quality, accuracy and consistency of data collected [5–9]. CDC conducted cognitive testing 
of a prototype VAERS 2.0 form with 22 volunteers of varying backgrounds and experiences, 
including physicians (9), nurses (4), pharmacists (2), medical office staff (1), persons aged 
65 years and older (3), and parents of young children (3), from November 2013 through 
January 2014, in Atlanta, Georgia. Eligibility criteria for volunteers was that they fell into 
one of the above categories and were willing to complete an in-person interview. Purposive 
sampling was used based on CDC contacts. Research shows that small sample sizes can 
provide adequate data – the goal of cognitive testing is to capture repeating themes, which 
usually emerge quickly [9].
We conducted in-person interviews using Cognitive Interviewing: A “How To” Guide [9] as 
our reference. One member of the two-person interview team was a behavioral scientist with 
experience in qualitative research. Pre-identified topics included: (1) initial impression of the 
revised form, (2) opinions on content, format, design and flow, (3) interpretation of language 
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(i.e., what information do people think they are being asked to provide and how do they 
understand response options), (4) how volunteers would complete the form (i.e., cognitive 
processes involved in formulating and providing responses), and (5) time required to 
complete the form. We asked volunteers to verbalize thoughts throughout the interview.
We used verbal probing techniques and documented body language and non-verbal 
communication cues. In addition to taking notes, we digitally recorded interviews. 
Interviews continued until repeating themes had been identified and new themes or ideas 
were no longer being expressed; often 45–60 min. Follow-up to clarify outstanding issues 
was necessary with five volunteers. CDC staff spent approximately 80 h preparing for and 
conducting interviews. Thematic analysis [10] included inductive (open- ended or non-
preconceived) and deductive (pre-identified or pre- conceived) approaches. Based on 
findings, we made further revisions to the proposed VAERS 2.0 form. The CDC Human 
Research Protection Office determined the activity did not qualify as research and 
Institutional Review Board approval was not required. Consent was obtained from all 
volunteers.
3. Results
Repeating themes from cognitive testing included recommendations to:
1. Shorten and simplify questions and the form overall. Initial impressions of the 
form were that it was visually cluttered, unnecessarily long, and confusing. We 
addressed these concerns by removing fine print at the top and bottom of the 
form (e.g., URL link to the VAERS website and HIPAA privacy rules) and for 
clarity, we revised or deleted text that did not contribute to understanding the 
intent of questions. For example, in a question about vaccinations given to 
pregnant women, we changed instructions from “. . . describe pregnancy history, 
key dates, and the event. . .” to “. . . describe the event, any pregnancy 
complications, and estimated due date if known. . .”.
2. Reorder questions in a more logical completion sequence. A repeating theme was 
that certain questions should be grouped together (e.g., questions about 
demographics or reporter information) and ordered in a way that made sense. In 
response, we reordered questions, within space constraints of the form, to the 
most logical left-to-right, top- to-bottom completion sequence, thereby allowing 
persons to complete the form with minimal skipping from one section to another.
3. Visually highlight essential questions (i.e., those asking for high value public 
health and regulatory information such as date and time of vaccination and date 
and time the AE started). Highlight features were (and would be) helpful, 
especially when reporters are under time-constraints. This was accomplished 
through color coding essential questions.
4. Deemphasize non-essential questions by moving them to the end of the form. 
Moving non-essential questions to the end prevents mental fatigue that occurs 
when a person is forced to maintain concentration for an extended period of time 
during form completion. Questions about race and ethnicity were moved to the 
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end because volunteers felt these questions were less relevant to them when 
reporting an AE. This was accomplished during the question reordering process.
Cognitive testing revealed different preferences for healthcare professionals compared to 
laypersons. Healthcare professionals wanted a savable computerized form to allow multiple 
users to independently work on sections, similar to how paperwork is completed in clinic 
office settings. Laypersons preferred less clinical terms and medical jargon – the data 
element “route and site of vaccine administration” was cited as an example. Factors that 
could influence the amount of time to complete the form varied between healthcare 
professionals and laypersons. For healthcare professionals, factors were clinic workload and 
severity of the AE – severe AEs would require more time to report. For laypersons, factors 
were time it would take to gather health records and to call or visit their healthcare provider. 
Estimated length of time to complete the form ranged from 5 to 30 min for healthcare 
professionals and 15 to 20 min for laypersons.
Interpretation of some questions was problematic. For example, physicians interpreted the 
question asking for “Responsible Physician,” which was meant to identify the best physician 
to contact if additional clinical information was needed, as implying liability(i.e., risk of 
being sued). This was not anticipated and resulted in a change in language to “Best doctor/
healthcare professional to contact about the adverse event.” Quotes from interviews are in 
Table 1.
4. Discussion
Cognitive testing yielded useful information that will help improve efficiency and data 
quality in VAERS reporting. Importantly, it identified discordance between the intended 
meaning of some questions (from the perspective of CDC and FDA scientists), and 
interpretation by healthcare professionals and laypersons. The findings challenged many 
assumptions. CDC and FDA scientists believed questions were generally clear and concise, 
and would be easily understood by both healthcare professionals and laypersons. However, 
testing revealed that some questions were confusing or non-specific, such as the meaning of 
“responsible physician,” and terms like “route and site” of vaccine administration. We 
assumed the length of the form and order of questions were satisfactory, but cognitive testing 
demonstrated that volunteers preferred a shorter, simplified form, with a more logical 
sequence of information and grouping together of similar data elements like demographics 
and clinic information.
There were differences in preferences between healthcare professionals and laypersons, with 
the former wanting a shorter form with focus on essential data elements, and the latter 
wanting plain language and less medical jargon. Healthcare professionals cited busy 
schedules and severity of the AE as factors that would influence time to complete the form 
(i.e., having to retrieve and review patient records). In contrast, laypersons cited factors like 
having to call or visit a clinic to get specific information, like vaccine lot number and route 
and site of administration.
Based on findings of the cognitive testing, CDC and FDA made revisions to the proposed 
VAERS 2.0 form and briefed federal advisory committees on changes [11–13]. The updated 
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form was also posted on the Federal Register for public comment [4]. Computer-based user 
testing was conducted with the updated version of the form, including testing on mobile 
devices like smartphones and tablets, which contributed to an additional round of revisions. 
Post-implementation cognitive testing with a more representative sample of volunteers will 
be considered as part of the evaluation process.
A limitation of our cognitive testing was the relatively small purposive sample of volunteers, 
which might preclude generalizing results to a broader population. However, representative 
samples are not an absolute requirement for cognitive testing. Rather, it is critically 
important to identify key repeating themes or problem areas, which often become apparent 
quickly during the course of interviews [9].
5. Conclusion
Cognitive testing revealed that brevity, simplicity, clarity, and ease of completion were 
desired traits in the reporting form. Suggestions from volunteer testers led to meaningful 
changes to the form and demonstrated the value of cognitive testing as a component of 
survey and questionnaire development. With training and practice, cognitive testing can be 
an effective tool for any public health program interested in creating or revising surveys and 
reporting forms.
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